Treatsma website reaches national news in Bhutan.
We are pleased to share with you the initiation of MANATEE, a new global Phase 2/3 clinical study that aims to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth in combination with risdiplam, in Spinal Muscular Atrophy (SMA).
TreatSMA Trustee Andi Thornton speaks with SMA UK Trustee Toby Mildon about mental health, treatments, University and work, health care and much more
New Clinical Study Planned to Evaluate the Potential Benefit of an Investigational Higher Dose of Nusinersen in People with SMA Previously Treated with Evrysdi® (risdiplam)
TreatSMA are extremely happy to announce that Lianne Harris has joined the team as a volunteer to assist with Fundraising and Events Co-ordination.
We are now listed as a charity on Amazon Smile. By choosing us as your selected charity Amazon will donate 0.5% of the net purchase price (excluding VAT, returns and shipping fees) of eligible purchases to us. You can set…